Previous 10 | Next 10 |
2023-07-27 13:46:53 ET More on Lipocine Lipocine stock dips after bridging study data of LPCN 1154 for postpartum depression Lipocine announces plans to focus on treating CNS disorders, shares rise ~5% Lipocine announces FDA accepted the marketing application for Tla...
2023-07-27 10:07:10 ET Gainers: Carmell Therapeutics ( CTCX ) +44% . Mallinckrodt ( MNK ) +35% . Evolus ( EOLS ) +28% . Lipocine ( LPCN ) +26% . Spok ( SPOK ) +23% . Losers: Mersana Therapeutics ( MRSN ) -77% . ...
LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis PR Newswire Met primary endpoint: treatment with LPCN 1148 increased L3 skeletal muscle index (L3-SMI) relative to placebo (P <0.01) Fewer hepatic encephalopathy (HE) events of grade >1 in the ...
Lipocine to Present at H.C. Wainwright Annual Neuropsychiatry Virtual Conference PR Newswire SALT LAKE CITY , June 14, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by lev...
Lipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023 PR Newswire Phase 2 proof-of-concept study of LPCN 1148 in male cirrhotic patients with sarcopenia is fully enrolled with topline 24-week results expected mid-2023 SALT LAKE CITY , June 7, 2023...
2023-05-16 09:47:57 ET Lipocine ( NASDAQ: LPCN ) stock fell ~6% on Tuesday after reporting data from a pilot pharmacokinetic (PK) bridge study of LPCN 1154 (oral brexanolone), versus IV brexanolone for postpartum depression (PPD). The study enrolled 12 people and e...
Positive Topline Clinical Results Support Streamlined Development Pathway for LPCN 1154, Lipocine's Oral Candidate for Rapid Relief of Depression PR Newswire Identified dosing regimen that enables reliance on a single confirmatory pivotal pharmacokinetic (PK) study to establis...
2023-05-11 06:49:36 ET Lipocine press release ( NASDAQ: LPCN ): Q1 GAAP EPS of -$0.04 misses by $0.01 . For further details see: Lipocine GAAP EPS of -$0.04 misses by $0.01
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2023 PR Newswire SALT LAKE CITY , May 11, 2023 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on treating Central Nervous System (CNS) disorders by ...
First Subject Dosed in the Clinical Bridge Study with Lipocine Depression Candidate, LPCN 1154 PR Newswire LPCN 1154 is an oral formulation of brexanolone in development for the rapid relief of postpartum depression (PPD) Topline study results expected in H1 2023 ...
News, Short Squeeze, Breakout and More Instantly...
Shares of Lipocine Inc. (NASDAQ: LPCN) traded at a new 52-week high today and are currently trading at $8.96. So far today, approximately 78,318 shares have been exchanged, as compared to an average 30-day volume of 32,701 shares. Lipocine Inc., a clinical-stage biopharmaceutical company, foc...
Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024 PR Newswire SALT LAKE CITY , June 10, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced that Phase 2 r...
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024 PR Newswire SALT LAKE CITY , May 9, 2024 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company, today announced financial results for the first quarter ended&...